Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term annual CD388 safety and immunogenicity study in healthy adults
ISRCTN20641445Phase 2Recruiting
- Sponsor
- hVIVO
- Start
- Nov 2025
- Modality
- Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retezrelvir in influenza, sponsored by hVIVO. Primary endpoint: Anti-drug antibody assessment. Started Nov 2025; status: recruiting.
02
Drugs
retezrelvir
03
Conditions
influenza
Beyond the preview
Go deeper on ISRCTN20641445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN20641445.